CCL20 and cancer: Cancer cells in Epstein-Barr virus (EBV) infection-positive Hodgkin's lymphoma patients can recruit Tregs by expressing the chemokine CCL20 via the EBV core antigen EBNA1 [35], which allows cancer cells to evade immune surveillance.